-+ 0.00%
-+ 0.00%
-+ 0.00%

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Barchart·12/30/2025 07:17:00
Listen to the news

TEL AVIV, Israel, Dec. 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, announced that the Israel Patent Office has granted a patent for its proprietary combination of opioids and N-acylethanolamines. This patent covers methods and formulations designed to potentiate the therapeutic effects of opioids while significantly reducing associated side effects, such as tolerance, dependence, and gastrointestinal issues.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.